tj darentang usd announcement, the company and the controlling shareholder Tianjin Pharmaceutical Group Co., Ltd. respectively intend to transfer 13% and 20% equity held by Sino-American Tianjin Stak Pharmaceutical Co., Ltd. to H-Force (China) Co., Ltd., with transaction prices of 1.759 billion RMB and 2.706 billion RMB respectively. Preliminary calculations indicate that this transaction is expected to generate investment income of approximately 1.7 billion RMB for the company. This transaction constitutes a related party transaction, which still needs to be submitted to the shareholders' meeting for approval. At the same time, this transaction also requires all parties to undergo concentration of business operators' anti-monopoly review and, in accordance with the regulations on equity transfer, complete the delivery of funds and the transfer of ownership registration before the transaction can be formally completed.